Mixtard 30 (Insulin Human)

Mixtard 30 is a premixed insulin used in the management of diabetes mellitus, a disorder of glucose regulation.

• Type 1 diabetes mellitus: provides basal and prandial insulin coverage to achieve target blood glucose levels.
• Type 2 diabetes mellitus: assists patients who need additional insulin to reach glycaemic goals when oral agents are insufficient.
• Insulin deficiency (e.g., after pancreatectomy): supplies the necessary exogenous insulin to replace absent endogenous production.

• Insulin human binds to insulin receptors on cell membranes, activating the receptor’s intrinsic tyrosine kinase activity. This triggers intracellular signaling cascades that promote glucose uptake in muscle and adipose tissue, inhibit hepatic glucose output, and facilitate glycogen synthesis, thereby lowering circulating blood glucose concentrations.

Mixtard 30 may cause a range of adverse reactions. Patients should be aware of both frequent and less common events.

Common Side Effects

• Hypoglycaemia: symptoms of low blood sugar such as shakiness, sweating, or confusion.
• Injection site reactions: redness, swelling, or itching at the injection site.
• Weight gain: increase in body weight associated with improved glycaemic control.
• Lipodystrophy: localized changes in fat tissue at injection sites.
• Edema: mild swelling of the extremities.

Serious or Rare Side Effects

• Severe hypoglycaemia leading to seizures or loss of consciousness.
• Allergic reactions including anaphylaxis, urticaria, or angio‑edema.
• Insulin antibody formation that may alter insulin effectiveness.
• Acute respiratory distress in rare hypersensitivity cases.
• Necrotising fasciitis at the injection site (extremely rare).

When using Mixtard 30, clinicians and patients should observe several safety measures.

• Blood glucose monitoring: check levels regularly to adjust dose and avoid hypoglycaemia.
• Dose adjustment during illness: illness or stress may increase insulin requirements.
• Caution with renal or hepatic impairment: reduced clearance can heighten hypoglycaemia risk.
• Avoid mixing with other insulin preparations unless specifically instructed.
• Use with beta‑blockers carefully: they may mask hypoglycaemic symptoms.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin therapy can be affected by several concomitant medicines. Interactions are grouped by clinical significance.

Major Interactions (Avoid)

• Sulfonylureas: additive hypoglycaemic effect.
• Meglitinides: increased risk of severe hypoglycaemia.
• Beta‑blockers: may conceal hypoglycaemia warning signs.

Moderate Interactions (Monitor Closely)

• Corticosteroids: can raise blood glucose, requiring dose increase.
• Thiazide diuretics: may cause modest hyperglycaemia.
• Oral contraceptives: may slightly reduce insulin sensitivity.